Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors

De Luca et al., International Journal of Molecular Sciences, doi:10.3390/ijms25020971, Jan 2024
In vitro study showing that novel selenium-containing compounds including benzoselenoates and carbamoselenoates inhibit SARS-CoV-2 main protease (Mpro) activity. After successfully expressing and purifying recombinant Mpro, authors find selenium derivatives exhibit dose-dependent inhibition with IC50 values in the micromolar range. Notably, the selenocarbamate 3c demonstrates potent sub-micromolar inhibition at 703.6 nM. These results highlight the potential of organoselenium agents, through their interactions with the catalytic cysteine, as effective Mpro inhibitors and antiviral therapeutics against SARS-CoV-2.
3 preclinical studies support the efficacy of selenium for COVID-19:
Selenium has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function4-6. Selenium may be beneficial for COVID-19 by inhibiting ferroptosis, an oxidative stress-induced cell death pathway implicated in COVID-19 pathogenesis7. Selenium enhances immune response, inhibits ROS production, and protects against ferroptosis via GPX4 induction8.
De Luca et al., 12 Jan 2024, peer-reviewed, 10 authors. Contact: claudiu.supuran@unifi.it (corresponding author), viviana.deluca@ibbr.cnr.it, vincenzo.carginale@cnr.it, andrea.angeli@unifi.it, alessio.nocentini@unifi.it, paola.gratteri@unifi.it, silvia.pratesi1@stud.unifi.it, damiano.tanini@unifi.it, antonella.capperucci@unifi.it, clemente.capasso@ibbr.cnr.it.
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors
Viviana De Luca, Andrea Angeli, Alessio Nocentini, Paola Gratteri, Silvia Pratesi, Damiano Tanini, Vincenzo Carginale, Antonella Capperucci, Claudiu T Supuran, Clemente Capasso
International Journal of Molecular Sciences, doi:10.3390/ijms25020971
The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (M pro ) as a prospective instrument in the repertoire to combat the virus. The cloning, expression, and purification of M pro , which plays a critical role in the viral life cycle, through heterologous expression in Escherichia coli in a completely soluble form produced an active enzyme. The hydrolysis of a specific substrate peptide comprising a six-amino-acid sequence (TSAVLQ) linked to a p-nitroaniline (pNA) fragment together with the use of a fluorogenic substrate allowed us to determine effective inhibitors incorporating selenium moieties, such as benzoselenoates and carbamoselenoates. The new inhibitors revealed their potential to proficiently inhibit M pro with IC 50 -s in the low micromolar range. Our study contributes to the development of a new class of protease inhibitors targeting M pro , ultimately strengthening the antiviral arsenal against COVID-19 and possibly, related coronaviruses.
Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/ijms25020971/s1. Conflicts of Interest: The authors declare no conflicts of interest.
References
Ali, Benedetti, Handzlik, Zwergel, Battistelli, The innovative potential of seleniumcontaining agents for fighting cancer and viral infections, Drug Discov. Today, doi:10.1016/j.drudis.2020.10.014
Amporndanai, Meng, Shang, Jin, Rogers et al., Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives, Nat. Commun, doi:10.1038/s41467-021-23313-7
Angeli, Carta, Donnini, Capperucci, Ferraroni et al., Selenolesterase enzyme activity of carbonic anhydrases, Chem. Commun, doi:10.1039/D0CC00995D
Angeli, Ferraroni, Capperucci, Tanini, Costantino et al., Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase Inhibition, ChemMedChem, doi:10.1002/cmdc.202200085
Angeli, Tanini, Nocentini, Capperucci, Ferraroni et al., A new class of carbonic anhydrase inhibitors, Chem. Commun, doi:10.1039/C8CC08562E
Badiani, Patel, Ziolkowski, Nielsen, Pfizer, The miracle vaccine for COVID-19?, Public Health Pract, doi:10.1016/j.puhip.2020.100061
Bhardwaj, Singh, Das, Purohit, Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs, Comput. Biol. Med, doi:10.1016/j.compbiomed.2020.104117
Buxeraud, Faure, Fougere, Nirmatrelvir/ritonavir (Paxlovid(R)), a treatment for COVID-19, Actual. Pharm
Cao, Goreshnik, Coventry, Case, Miller et al., De novo design of picomolar SARS-CoV-2 miniprotein inhibitors, Science, doi:10.1126/science.abd9909
Capasso, Nocentini, Supuran, Protease inhibitors targeting the main protease and papain-like protease of coronaviruses, Expert Opin. Ther. Pat, doi:10.1080/13543776.2021.1857726
Capperucci, Petrucci, Faggi, Tanini, Click Reaction of Selenols with Isocyanates: Rapid Access to Selenocarbamates as Peroxide-Switchable Reservoir of Thiol-peroxidase-Like Catalysts, Adv. Synth. Catal, doi:10.1002/adsc.202100611
Carabelli, Peacock, Thorne, Harvey, Hughes et al., SARS-CoV-2 variant biology: Immune escape, transmission and fitness, Nat. Rev. Microbiol, doi:10.1038/s41579-022-00841-7
Chavda, Vuppu, Mishra, Kamaraj, Patel et al., Recent review of COVID-19 management: Diagnosis, treatment and vaccination, Pharmacol. Rep, doi:10.1007/s43440-022-00425-5
Chen, Shao, Peng, Liang, Xu et al., Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection, Front. Pharmacol, doi:10.3389/fphar.2022.1035969
Citarella, Scala, Piperno, Micale, SARS-CoV-2 M pro : A Potential Target for Peptidomimetics and Small-Molecule Inhibitors, Biomolecules, doi:10.3390/biom11040607
Da Silva, Do Nascimento, Mendes, Guarines, Da Silva et al., Two Years into the COVID-19 Pandemic: Lessons Learned, ACS Infect. Dis, doi:10.1021/acsinfecdis.2c00204
Debnath, Agarwal, Kumar, Bedi, Selenium-Based Drug Development for Antioxidant and Anticancer Activity, Future Pharmacol, doi:10.3390/futurepharmacol2040036
Deniz, Uysal, Capasso, Supuran, Ozensoy Guler, Is carbonic anhydrase inhibition useful as a complementary therapy of COVID-19 infection?, J. Enzym. Inhib. Med. Chem, doi:10.1080/14756366.2021.1924165
Elnaggar, Elgazar, Gamal, Hamed, Elsayed et al., Identification of sulphonamide-tethered N-((triazol-4-yl)methyl)isatin derivatives as inhibitors of SARS-CoV-2 main protease, J. Enzym. Inhib. Med. Chem, doi:10.1080/14756366.2023.2234665
Eltayb, Abdalla, Rabie, Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species, ACS Omega, doi:10.1021/acsomega.2c03881
Flynn, Samant, Schneider-Nachum, Barkan, Yilmaz et al., Comprehensive fitness landscape of SARS-CoV-2 M pro reveals insights into viral resistance mechanisms, eLife, doi:10.7554/eLife.77433
Ghosh, Mishevich, Mesecar, Mitsuya, Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19, ChemMedChem, doi:10.1002/cmdc.202200440
Harris, Nasally Administered Monoclonal Antibody for COVID-19, JAMA-J. Am. Med. Assoc, doi:10.1001/jama.2023.4000
Hashemian, Sheida, Taghizadieh, Memar, Hamblin et al., Nirmatrelvir/Ritonavir): A new approach to COVID-19 therapy?, Biomed. Pharmacother, doi:10.1016/j.biopha.2023.114367
Hoffman, Kania, Brothers, Davies, Ferre et al., Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19, J. Med. Chem, doi:10.1021/acs.jmedchem.0c01063
Hou, Dong, Zhang, Wang, Su et al., Selenium as an emerging versatile player in heterocycles and natural products modification, Drug Discov. Today, doi:10.1016/j.drudis.2022.03.020
Hu, Xiong, Zhu, Zhang, Zhang et al., The SARS-CoV-2 main protease (M pro ): Structure, function, and emerging therapies for COVID-19, MedComm, doi:10.1002/mco2.151
Iacobucci, COVID-19: Evusheld protects the most vulnerable patients, analysis shows, BMJ-Br. Med. J, doi:10.1136/bmj.o2690
Ishihara, Koketsu, Fukuta, Nada, Reaction of lithium aluminum hydride with elemental selenium: Its application as a selenating reagent into organic molecules, J. Am. Chem. Soc, doi:10.1021/ja005800o
Jiang, Zou, Zeng, Zeng, Zhou et al., Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814, Mol. Biomed, doi:10.1186/s43556-023-00134-2
Jin, Du, Xu, Deng, Liu et al., Structure of M pro from SARS-CoV-2 and discovery of its inhibitors, Nature, doi:10.1038/s41586-020-2223-y
Kabinger, Stiller, Schmitzova, Dienemann, Kokic et al., Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat. Struct. Mol. Biol, doi:10.1038/s41594-021-00651-0
Kamal, Ramadan, Farraj, Bahig, Ezzat, The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review, Saudi Pharm. J, doi:10.1016/j.jsps.2022.03.002
Karniadakis, Mazonakis, Tsioutis, Papadakis, Markaki et al., Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence, Infect. Dis. Rep, doi:10.3390/idr15060061
Kelley, De Moor, Douglas, Renshaw, Traviglia, Monoclonal antibody therapies for COVID-19: Lessons learned and implications for the development of future products, Curr. Opin. Biotechnol, doi:10.1016/j.copbio.2022.102798
Kip, Mccreary, Collins, Minnier, Snyder et al., Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 A Cohort Study, Ann. Intern. Med, doi:10.7326/M22-1286
Kovacs, Kurtan, Varga, Nagy, Panyi et al., remdesivir) formulations inhibit initial membranecoupled events of SARS-CoV-2 infection due to their sulfobutylether-beta-cyclodextrin content, Br. J. Pharmacol, doi:10.1111/bph.16063
Li, Lin, Zhou, Zhong, Zeng et al., Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814, J. Mol. Biol, doi:10.1016/j.jmb.2022.167706
Li, Niu, A commentary on "The socio-economic implications of the coronavirus pandemic (COVID-19): A review, Int. J. Surg, doi:10.1016/j.ijsu.2021.106048
Li, Wang, Tian, Pang, Yang et al., COVID-19 vaccine development: Milestones, lessons and prospects, Signal Transduct. Target. Ther, doi:10.1038/s41392-022-00996-y
Liu, Wu, Huang, Hsu, Chuang et al., Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases, Expert Rev. Anti-Infect. Ther, doi:10.1080/14787210.2023.2284367
Lui, Guaraldi, Drug treatment of COVID-19 infection, Curr. Opin. Pulm. Med, doi:10.1097/MCP.0000000000000953
Ma, Hu, Townsend, Lagarias, Marty et al., Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors, ACS Pharmacol. Transl. Sci, doi:10.1021/acsptsci.0c00130
Markov, Ghafari, Beer, Lythgoe, Simmonds et al., The evolution of SARS-CoV-2, Nat. Rev. Microbiol, doi:10.1038/s41579-023-00878-2
Mengist, Dilnessa, Jin, Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease, Front. Chem, doi:10.3389/fchem.2021.622898
Mori, Capasso, Carta, Donald, Supuran, A deadly spillover: SARS-CoV-2 outbreak, Expert Opin. Ther. Pat, doi:10.1080/13543776.2020.1760838
Narayanan, Narwal, Majowicz, Varricchio, Toner et al., Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay, Commun. Biol, doi:10.1038/s42003-022-03090-9
Ng, Correia, Seagal, Degoey, Schrimpf et al., Antiviral Drug Discovery for the Treatment of COVID-19 Infections, Viruses, doi:10.3390/v14050961
Niknam, Jafari, Golchin, Danesh Pouya, Nemati et al., Potential therapeutic options for COVID-19: An update on current evidence, Eur. J. Med. Res, doi:10.1186/s40001-021-00626-3
Nocentini, Capasso, Supuran, Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: Where do we stand and where do we go?, Expert Opin. Drug Discov, doi:10.1080/17460441.2022.2052847
Pilote, Simard, Drolet, Remdesivir, VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects, J. Cardiovasc. Pharmacol, doi:10.1097/FJC.0000000000001321
Ravaghi, Naidoo, Mataria, Khalil, Hospitals early challenges and interventions combatting COVID-19 in the Eastern Mediterranean Region, PLoS ONE, doi:10.1371/journal.pone.0268386
Ravi, Eerike, Konda, Bisoi, Raj et al., Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. Monoclon. Antibodies Immunodiagn, Immunother, doi:10.1089/mab.2022.0036
Razali, Subbiah, Budiman, Technical Data of Heterologous Expression and Purification of SARS-CoV-2 Proteases Using Escherichia coli System, Data, doi:10.3390/data6090099
Sacco, Ma, Lagarias, Gao, Townsend et al., Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L, Sci. Adv, doi:10.1126/sciadv.abe0751
Sardar, Abdul-Khaliq, Ingar, Amaidia, Mansour, COVID-19 lockdown: A protective measure or exacerbator of health inequalities? A comparison between the United Kingdom and India.' a commentary on "the socio-economic implications of the coronavirus and COVID-19 pandemic: A review, Int. J. Surg, doi:10.1016/j.ijsu.2020.09.044
Scherf, Matschke, Rieger, Stock market reactions to COVID-19 lockdown: A global analysis, Financ. Res. Lett, doi:10.1016/j.frl.2021.102245
Sharun, Tiwari, Dhama, Dhama, Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence, Int. J. Surg, doi:10.1016/j.ijsu.2020.08.038
Tanini, Capperucci, Synthesis and Applications of Organic Selenols, Adv. Synth. Catal, doi:10.1002/adsc.202101147
Tanini, Carradori, Capperucci, Lupori, Zara et al., Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action, Eur. J. Med. Chem, doi:10.1016/j.ejmech.2021.113793
Tanini, Scarpelli, Ermini, Capperucci, Seleno-Michael Reaction of Stable Functionalised Alkyl Selenols: A Versatile Tool for the Synthesis of Acyclic and Cyclic Unsymmetrical Alkyl and Vinyl Selenides, Adv. Synth. Catal, doi:10.1002/adsc.201900168
Tanini, Tiberi, Gellini, Salvi, Capperucci, A Straightforward Access to Stable β-Functionalized Alkyl Selenols, Adv. Synth. Catal, doi:10.1002/adsc.201800602
Thakkar, Agarwal, Ranaweera, Ishiguro, Conda-Sheridan et al., De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain, RSC Med. Chem, doi:10.1039/D3MD00222E
Ullrich, Nitsche, The SARS-CoV-2 main protease as drug target, Bioorganic Med. Chem. Lett, doi:10.1016/j.bmcl.2020.127377
Wang, Yang, Yang, Hou, Tsai et al., Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug, Am. J. Cancer Res
Waugh, An overview of enzymatic reagents for the removal of affinity tags, Protein Expr. Purif, doi:10.1016/j.pep.2011.08.005
Wynter-Adams, Thomas-Brown, COVID-19 vaccine hesitancy in a developing country: Prevalence, explanatory factors and implications for the future, Public Health, doi:10.1016/j.puhe.2023.01.031
Yadav, Chaudhary, Jain, Chaudhary, Khanra et al., Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19, Cells, doi:10.3390/cells10040821
Yang, Ju, Wang, Jia, Wang et al., Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature, J. Clin. Lab. Anal, doi:10.1002/jcla.24880
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors, Science, doi:10.1126/science.abb3405
Zhao, Fang, Zhang, Zhang, Zhao et al., Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332, Protein Cell, doi:10.1007/s13238-021-00883-2
DOI record: { "DOI": "10.3390/ijms25020971", "ISSN": [ "1422-0067" ], "URL": "http://dx.doi.org/10.3390/ijms25020971", "abstract": "<jats:p>The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (Mpro) as a prospective instrument in the repertoire to combat the virus. The cloning, expression, and purification of Mpro, which plays a critical role in the viral life cycle, through heterologous expression in Escherichia coli in a completely soluble form produced an active enzyme. The hydrolysis of a specific substrate peptide comprising a six-amino-acid sequence (TSAVLQ) linked to a p-nitroaniline (pNA) fragment together with the use of a fluorogenic substrate allowed us to determine effective inhibitors incorporating selenium moieties, such as benzoselenoates and carbamoselenoates. The new inhibitors revealed their potential to proficiently inhibit Mpro with IC50-s in the low micromolar range. Our study contributes to the development of a new class of protease inhibitors targeting Mpro, ultimately strengthening the antiviral arsenal against COVID-19 and possibly, related coronaviruses.</jats:p>", "alternative-id": [ "ijms25020971" ], "author": [ { "affiliation": [ { "name": "Department of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy" } ], "family": "De Luca", "given": "Viviana", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-1470-7192", "affiliation": [ { "name": "Neurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy" } ], "authenticated-orcid": false, "family": "Angeli", "given": "Andrea", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3342-702X", "affiliation": [ { "name": "Neurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy" } ], "authenticated-orcid": false, "family": "Nocentini", "given": "Alessio", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9137-2509", "affiliation": [ { "name": "Neurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy" } ], "authenticated-orcid": false, "family": "Gratteri", "given": "Paola", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Chemistry “Ugo Schiff”, University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy" } ], "family": "Pratesi", "given": "Silvia", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-8930-3566", "affiliation": [ { "name": "Department of Chemistry “Ugo Schiff”, University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy" } ], "authenticated-orcid": false, "family": "Tanini", "given": "Damiano", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1842-494X", "affiliation": [ { "name": "Department of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy" } ], "authenticated-orcid": false, "family": "Carginale", "given": "Vincenzo", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Chemistry “Ugo Schiff”, University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy" } ], "family": "Capperucci", "given": "Antonella", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-4262-0323", "affiliation": [ { "name": "Neurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy" } ], "authenticated-orcid": false, "family": "Supuran", "given": "Claudiu T.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3314-2411", "affiliation": [ { "name": "Department of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy" } ], "authenticated-orcid": false, "family": "Capasso", "given": "Clemente", "sequence": "additional" } ], "container-title": "International Journal of Molecular Sciences", "container-title-short": "IJMS", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 1, 12 ] ], "date-time": "2024-01-12T12:47:16Z", "timestamp": 1705063636000 }, "deposited": { "date-parts": [ [ 2024, 1, 12 ] ], "date-time": "2024-01-12T13:12:11Z", "timestamp": 1705065131000 }, "funder": [ { "name": "Italian National Research Council" } ], "indexed": { "date-parts": [ [ 2024, 1, 13 ] ], "date-time": "2024-01-13T00:37:52Z", "timestamp": 1705106272579 }, "is-referenced-by-count": 0, "issue": "2", "issued": { "date-parts": [ [ 2024, 1, 12 ] ] }, "journal-issue": { "issue": "2", "published-online": { "date-parts": [ [ 2024, 1 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 1, 12 ] ], "date-time": "2024-01-12T00:00:00Z", "timestamp": 1705017600000 } } ], "link": [ { "URL": "https://www.mdpi.com/1422-0067/25/2/971/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "971", "prefix": "10.3390", "published": { "date-parts": [ [ 2024, 1, 12 ] ] }, "published-online": { "date-parts": [ [ 2024, 1, 12 ] ] }, "publisher": "MDPI AG", "reference": [ { "DOI": "10.1038/s41579-023-00878-2", "article-title": "The evolution of SARS-CoV-2", "author": "Markov", "doi-asserted-by": "crossref", "first-page": "361", "journal-title": "Nat. Rev. Microbiol.", "key": "ref_1", "volume": "21", "year": "2023" }, { "DOI": "10.1016/j.ijsu.2021.106048", "article-title": "A commentary on “The socio-economic implications of the coronavirus pandemic (COVID-19): A review”", "author": "Li", "doi-asserted-by": "crossref", "first-page": "106048", "journal-title": "Int. J. Surg.", "key": "ref_2", "volume": "95", "year": "2021" }, { "DOI": "10.1016/j.ijsu.2020.09.044", "article-title": "‘COVID-19 lockdown: A protective measure or exacerbator of health inequalities? A comparison between the United Kingdom and India.’ a commentary on “the socio-economic implications of the coronavirus and COVID-19 pandemic: A review”", "author": "Sardar", "doi-asserted-by": "crossref", "first-page": "189", "journal-title": "Int. J. Surg.", "key": "ref_3", "volume": "83", "year": "2020" }, { "DOI": "10.1016/j.frl.2021.102245", "article-title": "Stock market reactions to COVID-19 lockdown: A global analysis", "author": "Scherf", "doi-asserted-by": "crossref", "first-page": "102245", "journal-title": "Financ. Res. Lett.", "key": "ref_4", "volume": "45", "year": "2022" }, { "DOI": "10.1016/j.puhip.2020.100061", "article-title": "Pfizer: The miracle vaccine for COVID-19?", "author": "Badiani", "doi-asserted-by": "crossref", "first-page": "100061", "journal-title": "Public Health Pract.", "key": "ref_5", "volume": "1", "year": "2020" }, { "article-title": "SARS-CoV-2 variant biology: Immune escape, transmission and fitness", "author": "Carabelli", "first-page": "162", "journal-title": "Nat. Rev. Microbiol.", "key": "ref_6", "volume": "21", "year": "2023" }, { "DOI": "10.1038/s41392-022-00996-y", "article-title": "COVID-19 vaccine development: Milestones, lessons and prospects", "author": "Li", "doi-asserted-by": "crossref", "first-page": "146", "journal-title": "Signal Transduct. Target. Ther.", "key": "ref_7", "volume": "7", "year": "2022" }, { "DOI": "10.1002/cmdc.202200440", "article-title": "Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19", "author": "Ghosh", "doi-asserted-by": "crossref", "first-page": "e202200440", "journal-title": "ChemMedChem", "key": "ref_8", "volume": "17", "year": "2022" }, { "DOI": "10.1097/MCP.0000000000000953", "article-title": "Drug treatment of COVID-19 infection", "author": "Lui", "doi-asserted-by": "crossref", "first-page": "174", "journal-title": "Curr. Opin. Pulm. Med.", "key": "ref_9", "volume": "29", "year": "2023" }, { "DOI": "10.1371/journal.pone.0268386", "doi-asserted-by": "crossref", "key": "ref_10", "unstructured": "Ravaghi, H., Naidoo, V., Mataria, A., and Khalil, M. (2022). Hospitals early challenges and interventions combatting COVID-19 in the Eastern Mediterranean Region. PLoS ONE, 17." }, { "DOI": "10.1016/j.ijsu.2020.08.038", "article-title": "Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence", "author": "Sharun", "doi-asserted-by": "crossref", "first-page": "179", "journal-title": "Int. J. Surg.", "key": "ref_11", "volume": "82", "year": "2020" }, { "article-title": "Two Years into the COVID-19 Pandemic: Lessons Learned", "author": "Mendes", "first-page": "1758", "journal-title": "ACS Infect. Dis.", "key": "ref_12", "volume": "8", "year": "2020" }, { "DOI": "10.3390/futurepharmacol2040036", "article-title": "Selenium-Based Drug Development for Antioxidant and Anticancer Activity", "author": "Debnath", "doi-asserted-by": "crossref", "first-page": "595", "journal-title": "Future Pharmacol.", "key": "ref_13", "volume": "2", "year": "2022" }, { "DOI": "10.1016/j.drudis.2020.10.014", "article-title": "The innovative potential of seleniumcontaining agents for fighting cancer and viral infections", "author": "Ali", "doi-asserted-by": "crossref", "first-page": "256", "journal-title": "Drug Discov. Today", "key": "ref_14", "volume": "26", "year": "2021" }, { "DOI": "10.1016/j.drudis.2022.03.020", "article-title": "Selenium as an emerging versatile player in heterocycles and natural products modification", "author": "Hou", "doi-asserted-by": "crossref", "first-page": "2268", "journal-title": "Drug Discov. Today", "key": "ref_15", "volume": "27", "year": "2022" }, { "DOI": "10.1002/cmdc.202200085", "article-title": "Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase Inhibition", "author": "Angeli", "doi-asserted-by": "crossref", "first-page": "e202200085", "journal-title": "ChemMedChem", "key": "ref_16", "volume": "17", "year": "2022" }, { "DOI": "10.1016/j.ejmech.2021.113793", "article-title": "Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action", "author": "Tanini", "doi-asserted-by": "crossref", "first-page": "113793", "journal-title": "Eur. J. Med. Chem.", "key": "ref_17", "volume": "225", "year": "2021" }, { "DOI": "10.1038/s41586-020-2223-y", "article-title": "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors", "author": "Jin", "doi-asserted-by": "crossref", "first-page": "289", "journal-title": "Nature", "key": "ref_18", "volume": "582", "year": "2020" }, { "DOI": "10.1021/acsptsci.0c00130", "article-title": "Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors", "author": "Ma", "doi-asserted-by": "crossref", "first-page": "1265", "journal-title": "ACS Pharmacol. Transl. Sci.", "key": "ref_19", "volume": "3", "year": "2020" }, { "DOI": "10.1038/s41467-021-23313-7", "article-title": "Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives", "author": "Amporndanai", "doi-asserted-by": "crossref", "first-page": "3061", "journal-title": "Nat. Commun.", "key": "ref_20", "volume": "12", "year": "2021" }, { "DOI": "10.1111/bph.16063", "article-title": "Veklury(R) (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-beta-cyclodextrin content", "author": "Kovacs", "doi-asserted-by": "crossref", "first-page": "2064", "journal-title": "Br. J. Pharmacol.", "key": "ref_21", "volume": "180", "year": "2023" }, { "DOI": "10.1097/FJC.0000000000001321", "article-title": "Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects", "author": "Pilote", "doi-asserted-by": "crossref", "first-page": "616", "journal-title": "J. Cardiovasc. Pharmacol.", "key": "ref_22", "volume": "80", "year": "2022" }, { "DOI": "10.1016/j.copbio.2022.102798", "article-title": "Monoclonal antibody therapies for COVID-19: Lessons learned and implications for the development of future products", "author": "Kelley", "doi-asserted-by": "crossref", "first-page": "102798", "journal-title": "Curr. Opin. Biotechnol.", "key": "ref_23", "volume": "78", "year": "2022" }, { "DOI": "10.1089/mab.2022.0036", "article-title": "Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review", "author": "Ravi", "doi-asserted-by": "crossref", "first-page": "77", "journal-title": "Monoclon. Antibodies Immunodiagn. Immunother.", "key": "ref_24", "volume": "42", "year": "2023" }, { "article-title": "Nasally Administered Monoclonal Antibody for COVID-19", "author": "Harris", "first-page": "1142", "journal-title": "JAMA-J. Am. Med. Assoc.", "key": "ref_25", "volume": "329", "year": "2023" }, { "DOI": "10.7326/M22-1286", "article-title": "Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 A Cohort Study", "author": "Kip", "doi-asserted-by": "crossref", "first-page": "496", "journal-title": "Ann. Intern. Med.", "key": "ref_26", "volume": "176", "year": "2023" }, { "DOI": "10.1016/j.puhe.2023.01.031", "article-title": "COVID-19 vaccine hesitancy in a developing country: Prevalence, explanatory factors and implications for the future", "doi-asserted-by": "crossref", "first-page": "146", "journal-title": "Public Health", "key": "ref_27", "volume": "217", "year": "2023" }, { "DOI": "10.1136/bmj.o2690", "article-title": "COVID-19: Evusheld protects the most vulnerable patients, analysis shows", "author": "Iacobucci", "doi-asserted-by": "crossref", "first-page": "o2690", "journal-title": "BMJ-Br. Med. J.", "key": "ref_28", "volume": "379", "year": "2022" }, { "DOI": "10.1186/s40001-021-00626-3", "article-title": "Potential therapeutic options for COVID-19: An update on current evidence", "author": "Niknam", "doi-asserted-by": "crossref", "first-page": "6", "journal-title": "Eur. J. Med. Res.", "key": "ref_29", "volume": "27", "year": "2022" }, { "DOI": "10.3390/v14050961", "doi-asserted-by": "crossref", "key": "ref_30", "unstructured": "Ng, T.I., Correia, I., Seagal, J., DeGoey, D.A., Schrimpf, M.R., Hardee, D.J., Noey, E.L., and Kati, W.M. (2022). Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Viruses, 14." }, { "DOI": "10.1038/s41594-021-00651-0", "article-title": "Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis", "author": "Kabinger", "doi-asserted-by": "crossref", "first-page": "740", "journal-title": "Nat. Struct. Mol. Biol.", "key": "ref_31", "volume": "28", "year": "2021" }, { "DOI": "10.1016/j.jsps.2022.03.002", "article-title": "The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review", "author": "Kamal", "doi-asserted-by": "crossref", "first-page": "508", "journal-title": "Saudi Pharm. J.", "key": "ref_32", "volume": "30", "year": "2022" }, { "article-title": "Nirmatrelvir/ritonavir (Paxlovid(R)), a treatment for COVID-19", "author": "Buxeraud", "first-page": "10", "journal-title": "Actual. Pharm.", "key": "ref_33", "volume": "61", "year": "2022" }, { "DOI": "10.1002/jcla.24880", "article-title": "Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature", "author": "Yang", "doi-asserted-by": "crossref", "first-page": "e24880", "journal-title": "J. Clin. Lab. Anal.", "key": "ref_34", "volume": "37", "year": "2023" }, { "DOI": "10.1007/s43440-022-00425-5", "article-title": "Recent review of COVID-19 management: Diagnosis, treatment and vaccination", "author": "Chavda", "doi-asserted-by": "crossref", "first-page": "1120", "journal-title": "Pharmacol. Rep.", "key": "ref_35", "volume": "74", "year": "2022" }, { "DOI": "10.1016/j.biopha.2023.114367", "doi-asserted-by": "crossref", "key": "ref_36", "unstructured": "Hashemian, S.M.R., Sheida, A., Taghizadieh, M., Memar, M.Y., Hamblin, M.R., Bannazadeh Baghi, H., Sadri Nahand, J., Asemi, Z., and Mirzaei, H. (2023). Paxlovid (Nirmatrelvir/Ritonavir): A new approach to COVID-19 therapy?. Biomed. Pharmacother., 162." }, { "DOI": "10.1021/acsomega.2c03881", "article-title": "Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species", "author": "Eltayb", "doi-asserted-by": "crossref", "first-page": "5234", "journal-title": "ACS Omega", "key": "ref_37", "volume": "8", "year": "2023" }, { "DOI": "10.3390/cells10040821", "doi-asserted-by": "crossref", "key": "ref_38", "unstructured": "Yadav, R., Chaudhary, J.K., Jain, N., Chaudhary, P.K., Khanra, S., Dhamija, P., Sharma, A., Kumar, A., and Handu, S. (2021). Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells, 10." }, { "DOI": "10.1080/13543776.2020.1760838", "article-title": "A deadly spillover: SARS-CoV-2 outbreak", "author": "Mori", "doi-asserted-by": "crossref", "first-page": "481", "journal-title": "Expert Opin. Ther. Pat.", "key": "ref_39", "volume": "30", "year": "2020" }, { "DOI": "10.1080/13543776.2021.1857726", "article-title": "Protease inhibitors targeting the main protease and papain-like protease of coronaviruses", "author": "Capasso", "doi-asserted-by": "crossref", "first-page": "309", "journal-title": "Expert Opin. Ther. Pat.", "key": "ref_40", "volume": "31", "year": "2021" }, { "DOI": "10.1080/14756366.2021.1924165", "article-title": "Is carbonic anhydrase inhibition useful as a complementary therapy of COVID-19 infection?", "author": "Deniz", "doi-asserted-by": "crossref", "first-page": "1230", "journal-title": "J. Enzym. Inhib. Med. Chem.", "key": "ref_41", "volume": "36", "year": "2021" }, { "DOI": "10.3390/biom11040607", "doi-asserted-by": "crossref", "key": "ref_42", "unstructured": "Citarella, A., Scala, A., Piperno, A., and Micale, N. (2021). SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules, 11." }, { "DOI": "10.7554/eLife.77433", "article-title": "Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms", "author": "Flynn", "doi-asserted-by": "crossref", "first-page": "e77433", "journal-title": "eLife", "key": "ref_43", "volume": "11", "year": "2022" }, { "article-title": "The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19", "author": "Hu", "first-page": "e151", "journal-title": "MedComm (2020)", "key": "ref_44", "volume": "3", "year": "2022" }, { "DOI": "10.3389/fchem.2021.622898", "article-title": "Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease", "author": "Mengist", "doi-asserted-by": "crossref", "first-page": "622898", "journal-title": "Front. Chem.", "key": "ref_45", "volume": "9", "year": "2021" }, { "DOI": "10.1016/j.pep.2011.08.005", "article-title": "An overview of enzymatic reagents for the removal of affinity tags", "author": "Waugh", "doi-asserted-by": "crossref", "first-page": "283", "journal-title": "Protein Expr. Purif.", "key": "ref_46", "volume": "80", "year": "2011" }, { "DOI": "10.1126/science.abb3405", "article-title": "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "409", "journal-title": "Science", "key": "ref_47", "volume": "368", "year": "2020" }, { "DOI": "10.3390/data6090099", "doi-asserted-by": "crossref", "key": "ref_48", "unstructured": "Razali, R., Subbiah, V.K., and Budiman, C. (2021). Technical Data of Heterologous Expression and Purification of SARS-CoV-2 Proteases Using Escherichia coli System. Data, 6." }, { "DOI": "10.1126/sciadv.abe0751", "article-title": "Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L", "author": "Sacco", "doi-asserted-by": "crossref", "first-page": "eabe0751", "journal-title": "Sci. Adv.", "key": "ref_49", "volume": "6", "year": "2020" }, { "DOI": "10.1016/j.compbiomed.2020.104117", "article-title": "Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs", "author": "Bhardwaj", "doi-asserted-by": "crossref", "first-page": "104117", "journal-title": "Comput. Biol. Med.", "key": "ref_50", "volume": "128", "year": "2021" }, { "DOI": "10.1016/j.bmcl.2020.127377", "article-title": "The SARS-CoV-2 main protease as drug target", "author": "Ullrich", "doi-asserted-by": "crossref", "first-page": "127377", "journal-title": "Bioorganic Med. Chem. Lett.", "key": "ref_51", "volume": "30", "year": "2020" }, { "DOI": "10.1007/s13238-021-00883-2", "article-title": "Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332", "author": "Zhao", "doi-asserted-by": "crossref", "first-page": "689", "journal-title": "Protein Cell", "key": "ref_52", "volume": "13", "year": "2022" }, { "DOI": "10.3389/fphar.2022.1035969", "article-title": "Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection", "author": "Chen", "doi-asserted-by": "crossref", "first-page": "1035969", "journal-title": "Front. Pharmacol.", "key": "ref_53", "volume": "13", "year": "2022" }, { "DOI": "10.1186/s43556-023-00134-2", "article-title": "Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814", "author": "Jiang", "doi-asserted-by": "crossref", "first-page": "23", "journal-title": "Mol. Biomed.", "key": "ref_54", "volume": "4", "year": "2023" }, { "DOI": "10.1016/j.jmb.2022.167706", "article-title": "Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814", "author": "Li", "doi-asserted-by": "crossref", "first-page": "167706", "journal-title": "J. Mol. Biol.", "key": "ref_55", "volume": "434", "year": "2022" }, { "DOI": "10.3390/idr15060061", "article-title": "Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence", "author": "Karniadakis", "doi-asserted-by": "crossref", "first-page": "662", "journal-title": "Infect. Dis. Rep.", "key": "ref_56", "volume": "15", "year": "2023" }, { "DOI": "10.1080/14787210.2023.2284367", "doi-asserted-by": "crossref", "key": "ref_57", "unstructured": "Liu, T.H., Wu, J.Y., Huang, P.Y., Hsu, W.H., Chuang, M.H., Tsai, Y.W., Lai, C.C., and Huang, C.Y. (2023). Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases. Expert Rev. Anti-Infect. Ther., 1–8." }, { "DOI": "10.1002/adsc.202101147", "article-title": "Synthesis and Applications of Organic Selenols", "author": "Tanini", "doi-asserted-by": "crossref", "first-page": "5360", "journal-title": "Adv. Synth. Catal.", "key": "ref_58", "volume": "363", "year": "2021" }, { "DOI": "10.1002/adsc.201900168", "article-title": "Seleno-Michael Reaction of Stable Functionalised Alkyl Selenols: A Versatile Tool for the Synthesis of Acyclic and Cyclic Unsymmetrical Alkyl and Vinyl Selenides", "author": "Tanini", "doi-asserted-by": "crossref", "first-page": "2337", "journal-title": "Adv. Synth. Catal.", "key": "ref_59", "volume": "361", "year": "2019" }, { "DOI": "10.1002/adsc.201800602", "article-title": "A Straightforward Access to Stable β-Functionalized Alkyl Selenols", "author": "Tanini", "doi-asserted-by": "crossref", "first-page": "3367", "journal-title": "Adv. Synth. Catal.", "key": "ref_60", "volume": "360", "year": "2018" }, { "DOI": "10.1039/C8CC08562E", "article-title": "Selenols: A new class of carbonic anhydrase inhibitors", "author": "Angeli", "doi-asserted-by": "crossref", "first-page": "648", "journal-title": "Chem. Commun.", "key": "ref_61", "volume": "55", "year": "2019" }, { "DOI": "10.1039/D0CC00995D", "article-title": "Selenolesterase enzyme activity of carbonic anhydrases", "author": "Angeli", "doi-asserted-by": "crossref", "first-page": "4444", "journal-title": "Chem. Commun.", "key": "ref_62", "volume": "56", "year": "2020" }, { "DOI": "10.1002/adsc.202100611", "article-title": "Click Reaction of Selenols with Isocyanates: Rapid Access to Selenocarbamates as Peroxide-Switchable Reservoir of Thiol-peroxidase-Like Catalysts", "author": "Capperucci", "doi-asserted-by": "crossref", "first-page": "4256", "journal-title": "Adv. Synth. Catal.", "key": "ref_63", "volume": "363", "year": "2021" }, { "DOI": "10.1021/ja005800o", "article-title": "Reaction of lithium aluminum hydride with elemental selenium: Its application as a selenating reagent into organic molecules", "author": "Ishihara", "doi-asserted-by": "crossref", "first-page": "8408", "journal-title": "J. Am. Chem. Soc.", "key": "ref_64", "volume": "123", "year": "2001" }, { "DOI": "10.1126/science.abd9909", "article-title": "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "426", "journal-title": "Science", "key": "ref_65", "volume": "370", "year": "2020" }, { "DOI": "10.1039/D3MD00222E", "article-title": "De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain", "author": "Thakkar", "doi-asserted-by": "crossref", "first-page": "1722", "journal-title": "RSC Med. Chem.", "key": "ref_66", "volume": "14", "year": "2023" }, { "DOI": "10.1021/acs.jmedchem.0c01063", "article-title": "Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19", "author": "Hoffman", "doi-asserted-by": "crossref", "first-page": "12725", "journal-title": "J. Med. Chem.", "key": "ref_67", "volume": "63", "year": "2020" }, { "DOI": "10.1038/s42003-022-03090-9", "article-title": "Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay", "author": "Narayanan", "doi-asserted-by": "crossref", "first-page": "169", "journal-title": "Commun. Biol.", "key": "ref_68", "volume": "5", "year": "2022" }, { "article-title": "Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug", "author": "Wang", "first-page": "2535", "journal-title": "Am. J. Cancer Res.", "key": "ref_69", "volume": "10", "year": "2020" }, { "key": "ref_70", "unstructured": "Schrödinger Suite Release 2022-4 (2022). (a) Maestro v.13.2; (b) Prime, v.5.5; (c) Epik, v.6.0; (d) Impact, v.9.5; (e) Macromodel v.13.6. (f) Glide, v.9.5, Schrödinger, LLC." }, { "DOI": "10.1080/17460441.2022.2052847", "article-title": "Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: Where do we stand and where do we go?", "author": "Nocentini", "doi-asserted-by": "crossref", "first-page": "547", "journal-title": "Expert Opin. Drug Discov.", "key": "ref_71", "volume": "17", "year": "2022" }, { "DOI": "10.1080/14756366.2023.2234665", "article-title": "Identification of sulphonamide-tethered N-((triazol-4-yl)methyl)isatin derivatives as inhibitors of SARS-CoV-2 main protease", "author": "ElNaggar", "doi-asserted-by": "crossref", "first-page": "2234665", "journal-title": "J. Enzym. Inhib. Med. Chem.", "key": "ref_72", "volume": "38", "year": "2023" } ], "reference-count": 72, "references-count": 72, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/1422-0067/25/2/971" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Inorganic Chemistry", "Organic Chemistry", "Physical and Theoretical Chemistry", "Computer Science Applications", "Spectroscopy", "Molecular Biology", "General Medicine", "Catalysis" ], "subtitle": [], "title": "Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors", "type": "journal-article", "volume": "25" }